Harbin Medisan Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002900.SZ

Harbin Medisan Pharmaceutical Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 63.34 M

Harbin Medisan Pharmaceutical Co., Ltd. Total Non-Current Liabilities is USD 63.34 M for the year ending December 31, 2023, a -30.29% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Harbin Medisan Pharmaceutical Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 90.87 M, a 40.00% change year over year.
Harbin Medisan Pharmaceutical Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 64.91 M, a 313.98% change year over year.
Harbin Medisan Pharmaceutical Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 15.68 M, a 12.40% change year over year.
Harbin Medisan Pharmaceutical Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 13.95 M, a -0.67% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Shenzhen Stock Exchange: 002900.SZ

Harbin Medisan Pharmaceutical Co., Ltd.

CEO	Mr. Jian Fei Qin
IPO Date	Sept. 25, 2017
Location	China
Headquarters	Limin Development Zone
Employees	2,115
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Non-Alcoholic Beverages Personal Care Plastics Vaccines

Description

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical pharmaceutical dosage forms and APIs in China. It offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, body fluid balance infusion, and other medical fields. The company was founded in 1996 and is based in Harbin, China.

Key trends

Past 5 years